目的 探討異苷草酸鎂聯(lián)合生長抑素治療肝硬化患者的臨床療效。方法 選取2016年1月-2019年6月鄭州市第七人民醫(yī)院收治的120例肝硬化患者作為研究對象，根據(jù)不同治療方法將患者分為對照組和觀察組，每組各60例。對照組采取注射用生長抑素治療，將6 mg加入到48 mL的0.9% NaCl注射液中，以0.25 mg/h速度連續(xù)靜脈滴注。觀察組在對照組患者治療基礎上靜脈滴注異甘草酸鎂注射液，0.1 g以10%葡萄糖注射液250 mL稀釋，1次/d。兩組均連續(xù)治療4周。觀察兩組患者的臨床療效，同時比較兩組的肝功能指標和并發(fā)癥發(fā)生情況。結果 治療后，觀察組的治療總有效率為90.0%明顯高于對照組的60.0%（P<0.05）。治療后，兩組總膽紅素（TB）、丙氨酸氨基轉移酶（ALT）、天門冬氨酸氨基轉氨酶（AST）、堿性磷酸酶（ALP）水平均明顯低于治療前（P<0.05），且觀察組各項肝功能指標明顯低于對照組（P<0.05）。治療后，觀察組的各并發(fā)癥發(fā)生率低于對照組，其中消化道出血發(fā)生率明顯低于對照組（P<0.05）。結論 異苷草酸鎂聯(lián)合生長抑素治療肝硬化可有效改善患者肝功能，可降低上消化道出血等并發(fā)癥發(fā)生率，療效顯著，明顯優(yōu)于單一生長抑素治療，且安全性高，具有臨床推廣應用價值。

Objective To investigate the effects of magnesium isoglycyrrhizinate combined with somatostatin on patients with liver cirrhosis. Methods Patients (120 cases) with liver cirrhosis in the Seventh People's Hospital of Zhengzhou from January 2016 to June 2019 were enrolled. According to different treatment methods, they were divided into control and observation group, and each group had 60 cases. Patients in the control group were treated with Somatostatin for Injection, 6 mg was added to 0.9% 48 mL NaCl injection, and continuous intravenous infusion was performed at the rate of 0.25 mg/h. Patients in the observation group were iv administered with Magnesium Isoglycyrrhizinate Injection on the basis of control group, 0.1 g was diluted with 250 mL 10% glucose injection, once daily. Patients in two groups were treated for 4 weeks. The clinical efficacy in two groups were observed, and the liver function indexes, and the incidence of complications in two groups were compared. Results After treatment, the total effective rate in the observation group was 90.0%, which was significantly higher than 60.0% of the control group (P<0.05). After treatment, the levels of TB, ALT, AST, and ALP were lower than those before treatment (P<0.05), and the liver function indexes in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the incidence of complications in the observation group was lower than that in the control group, and the incidence of gastrointestinal bleeding was significantly lower than that in the control group (P<0.05). Conclusion Magnesium isoglycyrrhizinate combined with somatostatin in treatment of liver cirrhosis can effectively improve the liver function of patients, and reduce the incidence of complications such as upper digestive tract bleeding. The treatment has significant efficacy, is significantly better than single somatostatin treatment, with high safety. Therefore, it has clinical application value.

R975

河南省科技攻關項目（172102310370）